Randy Carpenter, MD, Co-Founder, will join us to share the update from Allos Pharma.
Allos Pharma was founded by Mark Bear, Randy Carpenter and Mads Matthiesen with the goal of developing arbaclofen for treatment of individuals with fragile X syndrome. We are committed to completing the work initiated at Seaside Therapeutics, securing FDA approval, and working to make arbaclofen available around the world.
About Randy Carpenter, MD:
Dr. Carpenter is currently a Co-Founder of Allos Pharma, Chief Medical Officer of the Rett Syndrome Research Trust, a Research Affiliate in the Department of Neuroscience at MIT, and a member of the Scientific Advisory Boards of EU-AIMS and of the Translational Neuroscience Center at Boston Children's Hospital. While in industry, he led translational medicine teams responsible for 8 successful IND submissions and over 50 GCP-compliant clinical trials. Prior to joining industry, his academic focus was in translational medicine. He is personally motivated by his experiences as the sibling of an individual with intellectual disability.
Chad Coberly, JD, Chief Executive Officer, will join us to share the update from Tetra Therapeutics.
Tetra Therapeutics is developing its lead drug candidate, BPN14770, targeted toward improvement in cognition, as a potential disease-modifying agent in Fragile X Syndrome. BPN14770 has positive Phase 2 clinical trial results in adults with Fragile X and Tetra is now preparing to launch a Phase 3 study as well as additional studies in juveniles and pediatric patients in the latter half of 2021.
About Chad Coberly, JD:
Chad has more than 25 years of experience, primarily in the areas of biotech regulatory, clinical, compliance, intellectual property, business development, litigation, and general corporate legal affairs. Prior to joining Tetra he served as the Chief Clinical & Legal Officer for Cohera Medical, where he led the clinical, regulatory and legal aspects of commercialization of the first-ever approved 100% synthetic absorbable surgical adhesive. He brings intellectual property experience from the law firm of Howard and Howard, and experience from Zassi Medical and the Surgical Group of the Stryker Corporation where he held regulatory and legal-related positions.
Chad holds a JD from Michigan State University and a bachelor’s degree in biomedical engineering from Tulane University. He also has conducted MBA studies at Boston University. He is admitted to practice before the U.S. Patent and Trademark Office and is a member of the Michigan Bar.
Joseph M. Palumbo, MD, Chief Medical Officer will join us to share the update from Zynerba.
Zynerba Pharmaceuticals is conducting a placebo-controlled clinical trial (known as RECONNECT) with ZYN002 in children and adolescents, ages 3 through 17, who have been diagnosed with Fragile X Syndrome (FXS). Zynerba is studying the efficacy and safety of ZYN002 in the treatment of behavioral symptoms of FXS. ZYN002 is a pharmaceutically manufactured transdermal cannabidiol gel that is applied to the skin of the upper arms/shoulders and is absorbed systemically.
About Joseph Palumbo, MD:
Joseph M. Palumbo, MD is the Chief Medical Officer at Zynerba and a Board Certified Psychiatrist who has held leadership positions in academia and international development of new medicines. He is a physician-scientist whose teams have achieved global regulatory approvals in adult and childhood neuroscience, including the first treatment approved for the treatment of autism, and the first molecule shown to slow the progression of amyotrophic lateral sclerosis.
